The Prediction of HER2-Targeted Treatment Response Using (64)Cu-Tetra-Azacyclododecanetetra-Acetic Acid (DOTA)-Trastuzumab PET/CT in Metastatic Breast Cancer: A Case Report

A 45-year-old woman diagnosed with breast cancer reported disease progression in the form of metastatic lung and recurrent breast lesions following chemotherapy and human epidermal growth factor receptor 2 (HER2)-targeted therapy. The patient underwent (64)Cu-tetra-azacyclododecanetetra-acetic acid...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Inki, Lim, Ilhan, Byun, Byung Hyun, Kim, Byung Il, Choi, Chang Woon, Lee, Kyo Chul, Kang, Choong Mo, Seong, Min-Ki, Kim, Hyun-Ah, Noh, Woo Chul, Lim, Sang Moo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Breast Cancer Society 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876541/
https://www.ncbi.nlm.nih.gov/pubmed/35133094
http://dx.doi.org/10.4048/jbc.2022.25.e5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876541/
https://www.ncbi.nlm.nih.gov/pubmed/35133094
http://dx.doi.org/10.4048/jbc.2022.25.e5

Ejemplares similares